Certara (NASDAQ:CERT) Hits New 1-Year Low – Here’s What Happened

Certara, Inc. (NASDAQ:CERT) shares hit a new 52-week low on Thursday . The company traded as low as $9.46 and last traded at $9.52, with a volume of 13945 shares traded. The stock had previously closed at $9.55.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CERT. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Friday, September 27th. Robert W. Baird dropped their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Finally, Barclays dropped their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Certara has a consensus rating of “Hold” and an average target price of $15.92.

Certara Trading Down 0.7 %

The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The business’s fifty day simple moving average is $10.82 and its 200 day simple moving average is $13.30.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same quarter in the previous year, the business posted $0.06 EPS. The firm’s revenue was up 10.7% compared to the same quarter last year. Sell-side analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Insider Activity at Certara

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. This represents a 33.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Institutional Trading of Certara

A number of institutional investors have recently made changes to their positions in CERT. Blue Trust Inc. acquired a new stake in Certara during the second quarter valued at approximately $26,000. Innealta Capital LLC acquired a new stake in Certara during the second quarter valued at approximately $36,000. KBC Group NV lifted its stake in Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after purchasing an additional 1,584 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Certara during the second quarter valued at approximately $152,000. Finally, Algert Global LLC acquired a new stake in Certara during the second quarter valued at approximately $156,000. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.